JenniferAnnSchranzMD

Physician

Are you Dr. Schranz?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 9 invites waiting!
Read the latest clinical news, personalized to your specialty.

Dr. Jennifer Schranz, MD is an infectious disease specialist in Phoenixville, Pennsylvania. She is currently licensed to practice medicine in Pennsylvania.

Stony Brook Medicine/University HospitalFellowship, Infectious Disease, 1993 - 1995
University of Toronto Faculty of MedicineClass of 1989

PubMed

589 citations
Anidulafungin versus Fluconazole for Invasive Candidiasis
Annette C. Reboli, Coleman Rotstein, Peter G. Pappas, Stanley W. Chapman, Daniel H. Kett
The New England Journal of Medicine. 2007-06-14
141 citations
Safety and Pharmacokinetics of Intravenous Anidulafungin in Children with Neutropenia at High Risk for Invasive Fungal Infections
Daniel K. Benjamin, Timothy A. Driscoll, Nita L. Seibel, Corina E. Gonzalez, Maureen Roden
Antimicrobial Agents and Chemotherapy. 2006-02-01
65 citations
Safety and Pharmacokinetics of Coadministered Voriconazole and Anidulafungin
James A. Dowell, Jennifer Schranz, Alice Baruch, Grover Foster
Journal of Clinical Pharmacology. 2005-12-01

Nabriva to Present Data at the CHEST Annual Meeting Demonstrating the Safety and Efficacy of Newly FDA-Approved XENLETA (Lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)October 15th, 2019
Lefamulin Evaluation Against Pneumonia 2 (LEAP 2) Study Results Published in the Journal of the American Medical AssociationSeptember 27th, 2019
Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults with Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical TrialSeptember 27th, 2019
Join now to see all